Cash Dividend On The Way From Orchid Island Capital (ORC)

Looking at the universe of stocks we cover at Dividend Channel, on 5/21/15, Orchid Island Capital, Inc. (ORC) will trade ex-dividend, for its monthly dividend of $0.18, payable on 5/29/15. As a percentage of ORC's recent stock price of $14.15, this dividend works out to approximately 1.27%, so look for shares of Orchid Island Capital, Inc. to trade 1.27% lower — all else being equal — when ORC shares open for trading on 5/21/15.

START SLIDESHOW:
Click here to learn which 25 S.A.F.E. dividend stocks should be on your radar screen »

Below is a dividend history chart for ORC, showing historical dividends prior to the most recent $0.18 declared by Orchid Island Capital, Inc.:

ORC+Dividend+History+Chart

In general, dividends are not always predictable; but looking at the history above can help in judging whether the most recent dividend from ORC is likely to continue, and whether the current estimated yield of 15.27% on annualized basis is a reasonable expectation of annual yield going forward.The chart below shows the one year performance of ORC shares, versus its 200 day moving average:

Orchid Island Capital, Inc. 200 Day Moving Average Chart

Looking at the chart above, ORC's low point in its 52 week range is $12.50 per share, with $14.99 as the 52 week high point — that compares with a last trade of $14.15.

In Tuesday trading, Orchid Island Capital, Inc. shares are currently up about 0.1% on the day.

More from Stocks

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

3 Great Stock Market Sectors Millennials Should Invest In

3 Great Stock Market Sectors Millennials Should Invest In

Why Millennials Are Ditching Stocks for ETFs

Why Millennials Are Ditching Stocks for ETFs

Trump's 'Space Force' Could Launch a $1 Trillion Industry, Morgan Stanley Says

Trump's 'Space Force' Could Launch a $1 Trillion Industry, Morgan Stanley Says

Abiomed Stock Should Rise Some 12% From Here, Piper Jaffray Analyst Says

Abiomed Stock Should Rise Some 12% From Here, Piper Jaffray Analyst Says